Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Pediatrics · Congenital Adrenal Hyperplasia

Are CAH Newborn Screening Results Often False Positives?

At a Glance

A positive CAH newborn screen does not confirm congenital adrenal hyperplasia. High 17-OHP can result from prematurity, low birth weight, early sample collection, or newborn illness, so doctors use repeat or confirmatory testing while urgently checking babies with concerning symptoms.

Yes, false positives are very common with the congenital adrenal hyperplasia (CAH) newborn screening test [1][2]. If your baby’s doctor just called to tell you the newborn screen was positive, it is understandable to feel worried. However, a positive newborn screen is simply a signal that more testing is needed, not a final diagnosis [1].

While many abnormal screens do not result in a CAH diagnosis, every positive screen requires prompt medical attention.

Immediate Safety Considerations

A baby with severe, salt-wasting CAH may initially look well before their condition rapidly worsens [3].

  • Follow-up urgency: It is critical to contact the pediatrician or newborn screening program promptly to ask if the baby needs an urgent evaluation today or a routine repeat test.
  • When to seek emergency care: Medical guidelines advise going to the emergency room immediately if a baby experiences poor feeding, repeated vomiting, unusual sleepiness or difficulty waking, extreme weakness, fewer wet diapers, rapid weight loss, or appears generally unwell. Do not wait for final screening results if these symptoms appear [3].

Why do false positives happen?

The standard first-step newborn screen for CAH measures a hormone called 17-hydroxyprogesterone (17-OHP) [1]. In babies with the most common form of CAH (21-hydroxylase deficiency), 17-OHP builds up to high levels [1]. This initial test is very sensitive to ensure no cases are missed, but it is not highly specific, meaning it frequently flags babies who do not have CAH [4][2].

A baby’s 17-OHP levels can be temporarily elevated for several reasons:

  • Premature birth or low birth weight: The adrenal glands in premature and smaller babies are still developing. This immaturity often causes their 17-OHP levels to naturally run higher than in full-term babies [1][5].
  • Early sample collection: A baby’s 17-OHP levels naturally surge during the first 24 hours of life. If the heel-prick blood sample is collected too soon after birth, the result can exceed the screening cutoff [1][6].
  • Stress or illness: The physical stress of being a newborn, especially if the baby experiences complications like an infection (sepsis), breathing issues, low blood sugar, or birth asphyxia, can cause the adrenal glands to release more hormones and artificially inflate 17-OHP levels [7][8].

What happens next?

Because false positives are common, screening programs use follow-up steps to figure out if the high 17-OHP is due to CAH or another factor. Doctors determine the urgency based on how high the result was and the baby’s overall health:

  • Second-tier testing: Some state labs automatically run a more precise test on the original blood spot if the first result is high [9][10]. This test, called LC-MS/MS (liquid chromatography-tandem mass spectrometry), looks for a broader profile of hormones. It measures a hormone called 21-deoxycortisol, which tends to remain normal in premature or stressed babies without CAH [1][11]. This step can substantially reduce false positives, though it does not replace a doctor’s final evaluation [12].
  • A repeat newborn screen: If the initial result was borderline, a doctor or the lab may request a second heel-prick sample to see if the 17-OHP levels have dropped [9][13]. Screening cutoffs are often adjusted based on a baby’s birth weight and gestational age to improve accuracy [5].
  • Confirmatory blood tests: For markedly high screens, or if a baby appears unwell, doctors will promptly order a standard blood draw (serum test) [9][14]. This checks exact adrenal hormone levels alongside blood salts (electrolytes like sodium and potassium) and glucose, which can quickly identify if a baby is in a dangerous adrenal crisis.

Common questions in this guide

Are false-positive CAH newborn screening results common?
Yes. The first CAH screen is designed to catch nearly all affected babies, so it uses a sensitive test that can also flag babies who do not have CAH. A positive result means more testing is needed; it is not a diagnosis.
Does a positive CAH newborn screen mean my baby has CAH?
No. A positive screen shows that 17-hydroxyprogesterone, or 17-OHP, was higher than the screening cutoff and needs follow-up. Doctors interpret the result with the baby’s birth weight, gestational age, age at collection, health, and confirmatory tests.
Why can a baby without CAH have a high 17-OHP level?
Prematurity or low birth weight can raise 17-OHP because the adrenal glands are still developing. Levels may also be higher when the sample is collected during the first 24 hours or when a newborn is stressed or ill, such as with infection, breathing problems, low blood sugar, or birth asphyxia.
What testing happens after an abnormal CAH newborn screen?
Depending on the result and the baby’s health, the lab may perform a more specific laboratory test called LC-MS/MS on the original blood spot, request a repeat heel-prick screen, or order blood tests. Blood testing may measure adrenal hormones, sodium and potassium, and glucose to look for signs of a serious hormone or salt imbalance.
What symptoms mean my baby needs emergency care after a positive CAH screen?
Seek emergency care immediately if your baby has poor feeding, repeated vomiting, unusual sleepiness or trouble waking, marked weakness, fewer wet diapers, rapid weight loss, or appears very unwell. Do not wait for final screening results when these symptoms are present, because severe salt-wasting CAH can worsen quickly.
How quickly should I contact a doctor about a positive CAH screen?
Contact your baby’s pediatrician or newborn screening program promptly to learn whether the result needs same-day evaluation or a routine repeat test. The urgency depends on how high the 17-OHP result is and whether your baby has symptoms; a pediatric endocrinologist may be involved.

Get notified when new evidence is published on Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, simple virilizing form.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    Congenital Adrenal Hyperplasia: Time to Replace 17OHP with 21-Deoxycortisol.

    Miller WL

    Hormone research in paediatrics 2019; (91(6)):416-420 doi:10.1159/000501396.

    PMID: 31450227
  2. 2

    The use of liquid chromatography-tandem mass spectrometry in newborn screening for congenital adrenal hyperplasia: improvements and future perspectives.

    de Hora M, Heather N, Webster D, et al.

    Frontiers in endocrinology 2023; (14()):1226284 doi:10.3389/fendo.2023.1226284.

    PMID: 37850096
  3. 3

    Four Consecutive False Negative Newborn Screens in a Patient with Classical Congenital Adrenal Hyperplasia: A Case Report

    Rizzuto P, Gangat M, Khattab A, Marshall I

    Journal of clinical research in pediatric endocrinology 2026; (18(Suppl 1)):92-96 doi:10.4274/jcrpe.galenos.2025.2024-10-16.

    PMID: 41797552
  4. 4

    Measurement of 17-Hydroxyprogesterone by LCMSMS Improves Newborn Screening for CAH Due to 21-Hydroxylase Deficiency in New Zealand.

    de Hora MR, Heather NL, Patel T, et al.

    International journal of neonatal screening 2020; (6(1)):6.

    PMID: 33073005
  5. 5

    Combined Gestational Age- and Birth Weight-Adjusted Cutoffs for Newborn Screening of Congenital Adrenal Hyperplasia.

    Pode-Shakked N, Blau A, Pode-Shakked B, et al.

    The Journal of clinical endocrinology and metabolism 2019; (104(8)):3172-3180 doi:10.1210/jc.2018-02468.

    PMID: 30865229
  6. 6

    Outcome of Newborn Screening for Congenital Adrenal Hyperplasia at Two Time Points.

    Eshragh N, Doan LV, Connelly KJ, et al.

    Hormone research in paediatrics 2020; (93(2)):128-136 doi:10.1159/000508075.

    PMID: 32659761
  7. 7

    Evaluation of factors associated with elevated newborn 17-hydroxyprogesterone levels.

    Anandi VS, Shaila B

    Journal of pediatric endocrinology & metabolism : JPEM 2017; (30(6)):677-681.

    PMID: 28489558
  8. 8

    Newborn Screening Protocols and Positive Predictive Value for Congenital Adrenal Hyperplasia Vary across the United States.

    Speiser PW, Chawla R, Chen M, et al.

    International journal of neonatal screening 2020; (6(2)) doi:10.3390/ijns6020037.

    PMID: 32832708
  9. 9

    Evaluation of a Two-Tier Screening Pathway for Congenital Adrenal Hyperplasia in the New South Wales Newborn Screening Programme.

    Lai F, Srinivasan S, Wiley V

    International journal of neonatal screening 2020; (6(3)):63 doi:10.3390/ijns6030063.

    PMID: 33117905
  10. 10

    21-deoxycortisol as a second-tier test in congenital adrenal hyperplasia newborn screening in The Netherlands: two-year evaluation.

    Olthof A, Bouva MJ, Claahsen-van der Grinten HL, et al.

    Archives of disease in childhood 2025; (111(1)):62-68 doi:10.1136/archdischild-2025-328929.

    PMID: 40780708
  11. 11

    Second-tier Testing for 21-Hydroxylase Deficiency in the Netherlands: A Newborn Screening Pilot Study.

    Stroek K, Ruiter A, van der Linde A, et al.

    The Journal of clinical endocrinology and metabolism 2021; (106(11)):e4487-e4496 doi:10.1210/clinem/dgab464.

    PMID: 34171085
  12. 12

    Neonatal Screening for CAH in Sweden-Results of Implementing Second-Tier Testing.

    Engström K, Zetterström RH, Wedell A, Nordenström A

    International journal of neonatal screening 2026; (12(2)) doi:10.3390/ijns12020029.

    PMID: 42201221
  13. 13

    Newborn screening for congenital adrenal hyperplasia: a 3 years study embedded in 25 years of regional experience in Italy.

    Tuli G, Munarin J, Pavanello E, De Sanctis L

    Endocrine 2026; (91(1)).

    PMID: 42803878
  14. 14

    Efficacy of Liquid-chromatography and Radioimmunoassay in False-positives' Drop-off in CAH Newborn Screening.

    Carvalho DF, Lima-Valassi HP, Hayashi GY, et al.

    The Journal of clinical endocrinology and metabolism 2026; (111(8)):2210-2219 doi:10.1210/clinem/dgag107.

    PMID: 41811754

This page is for informational purposes only and does not constitute medical advice. It cannot determine whether your baby has CAH; contact your pediatrician or newborn screening program promptly about a positive result, and seek emergency care for concerning symptoms.